LOGIN  |  REGISTER
Amneal Pharmaceuticals
Assertio

HealthEquity Sets Date to Announce Fiscal Year End Results

March 05, 2024 | Last Trade: US$91.54 0.45 0.49

DRAPER, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its fourth quarter and fiscal year end 2024 financial results following the close of regular stock market trading hours on Tuesday, March 19, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, March 19, 2024, at 4:30 p.m. ET during which management will review the Company’s financial results.

HealthEquity Fourth Quarter and Fiscal Year End 2024 Results Conference Call

Date:March 19, 2024
Time:4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time
Dial-In:1-833-630-1956 (US and Canada) 1-412-317-1837 (International)
Conference ID:HealthEquity, Inc. call
Webcast:ir.healthequity.com

A replay of the conference call will be made available on the Company’s website at ir.healthequity.com.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 15 million benefit accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.

Investor Relations Contact:
Richard Putnam
801-727-1000
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB